CD44 and breast cancer: As CD44 is known to be overexpressed on BCSCs, surface marker-targeting ligand-conjugated drug delivery systems, such as liposomes, could be used to target BCSCs and enhance the overall therapeutic efficacy of drugs against breast cancer [13,14,15].